nanoigel

NanoIgel is a preclinical-stage biotechnology company developing a proprietary nanoparticle-based hydrogel platform for the sustained and localized delivery of therapeutics. The company's technology is designed to improve the efficacy and safety of drugs by providing controlled release at the site of administration, reducing systemic side effects and the need for frequent dosing. NanoIgel's primary focus areas include the management of post-operative pain and the treatment of chronic inflammatory conditions such as osteoarthritis. By leveraging its unique biomaterials expertise, the company aims to transform standard-of-care treatments across multiple therapeutic areas including oncology and pain management.